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Abstract
Background: A commonly used measure to reflect the intake of the long-chain omega-3 fatty acids EPA and DHA
is the omega-3 index, defined as the sum of EPA + DHA as % of total fatty acids in erythrocyte membrane. When
the omega-3 index changes it follows that the relative fractions of other fatty acids in the membrane are also
changed. In the present study, increasing doses of a preparation of omega-3 rich phospholipids extracted from krill
oil were administered orally to non-human primates for 12 weeks and the time course of EPA, DHA and 22 other
fatty acids in erythrocytes was determined bi-weekly during treatment and for 8 weeks after cessation of treatment.
Plasma concentrations of six endocannabinoid-type mediators being downstream metabolites of some fatty acids
analyzed in erythrocytes were also determined.
Methods: Six diabetic, dyslipidemic non-human primates were included, three in a vehicle control group and three
being treated with the omega-3 rich phospholipid preparation. The vehicle control and test items were given daily
by gavage and the test item doses were 50, 150 and 450 mg phospholipids/kg/day. Each dose level was given for
four weeks. Blood was sampled at baseline and thereafter bi-weekly. Fatty acids were determined in erythrocytes
by methylation followed by gas-chromatography. Endocannabinoids and endocannabinoid-like mediators were
analyzed in plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry.
Results: The treatment resulted in a dose-related increase in the fraction of EPA and DHA in erythrocyte
membranes and a dose-related decrease of other poly-unsaturated fatty acids, in particular omega-6
polyunsaturated fatty acids. Erythrocyte concentrations of saturated fatty acids remained unchanged throughout
the experiment. Plasma concentrations of endocannabinoids and endocannabinoid-like mediators changed
accordingly as those being downstream arachidonic acid decreased, downstream of the saturated palmitic and
oleic acids remained unchanged while a downstream EPA metabolite increased.
Conclusion: Increasing the omega-3 index by administering an omega-3 rich phospholipid extracted from krill oil
did not alter the ratio of unsaturated vs. saturated fatty acids in the erythrocyte membranes but only the relative
concentrations of unsaturated fatty acids, in particular unsaturated omega-6 fatty acids. Concentrations of saturated
fatty acids remained unchanged.
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Background
The long-chain omega-3 fatty acids (FAs) eicosapenta-
enoic acid (EPA; C20:5n3) and docosahexaenoic acid
(DHA; C22:6n3) are only to a very little extent produced
by the human body but high levels can be obtained if
they are supplied via the diet. EPA and DHA are found
in marine sources, and a diet rich in fatty fish like mack-
erel, salmon and anchovies will secure a high intake of
these FAs. A large number of scientific publications over
the last few decades have demonstrated numerous bene-
ficial health effects of a high intake of these long-chain
omega-3 FAs (for a review, see [1]) and this has led to a
significant industry delivering dietary supplements con-
taining one or both of these two FAs. The source of the
omega-3 s in these products is for the most part fatty
fish, but various crustacean species like krill [2] and co-
pepods [3], as well as algae [4], are also utilized.
The omega-3 index is often used to describe the levels
of omega-3 FAs in the body. This index is defined as the
percentage of EPA +DHA in erythrocyte membranes rela-
tive to the total amount of FAs in the membrane [5]. The
analytical method commonly applied for the determin-
ation of the index in erythrocytes is gas chromatography
following methylation of the fatty acid [6]. The index in
humans is normally varying from about 2–3%, indicating
a low EPA and DHA intake, up to about 11–12% which
indicates a high intake [5].
Since an increased intake of long-chain omega-3 FAs
will increase the fraction of EPA and DHA in the erythro-
cyte membrane it follows that the relative content of all or
some of the other fatty acids and, subsequently, of their
bioactive derivatives, must decrease, with a potential bio-
logical impact possibly beyond the mere alteration of the
physiological function of those fatty acids. In the present
study, increasing doses of a preparation of omega-3 rich
phospholipids from krill oil was administered orally to
non-human primates for a total of 12 weeks and the time
course of the FA profiles in their erythrocytes was deter-
mined at baseline, during treatment and also after cessa-
tion of treatment. In addition to EPA and DHA, 22 FAs
with an abundance varying from a fraction of a percent
up to more than 20% at baseline were analyzed bi-
weekly to investigate which of these were changed in
the membranes when increasing amounts of EPA and
DHA were administered. Furthermore, the concentra-
tions of the two endocannabinoids, anandamide and 2-
arachidonoylglycerol (2-AG), and four acylethanolamide
endocannabinoid-like mediators, i.e. EPA-ethanolamide,
DHA-ethanolamide, oleoylethanolamide and palmitoy-
lethanolamide, were determined in plasma bi-weekly. The
two endocannabinoids are downstream metabolites of
arachidonic acid while the four endocannabinoid-like
compounds are the ethanolamides of EPA, DHA, oleic acid
and palmitic acid, respectively, [7] and it was expected that
their plasma concentrations would reflect changes in
the abundance of their parent FA in the membranes
(see [8] and [9] for examples of such effects of krill
preparations in humans and mice, respectively). Endo-
cannabinoids and long-chain acetylethanolamides are
known to have marked biological effects and changing
the concentrations of these might potentially affect
physiological processes in several organ systems since
the receptors of these lipid mediators are widely distrib-
uted in the whole organism [10].
The data reported in this article originate from a
study which also investigated the effects of the
phospholipid preparation on several parameters
known to be risk factors for development of cardio-
vascular disease; serum cholesterols, apolipoproteins,
triglycerides, inflammatory biomarkers and diabetes
biomarkers. Selected safety parameters were also ana-
lyzed. The results from this part of the study are re-
ported separately [11].
Results
The relative fraction of the two main omega-3 fatty acids
present in the phospholipid preparation administered to
the non-human primates, EPA and DHA, increased
dose-dependently in the treated animals (Fig. 1) while in
the controls, only a minor change in the levels of these
FAs was observed. For EPA, the levels in the treated ani-
mals increased from <1% at baseline to a mean of 8% at
the end of treatment while DHA levels increased from a
mean of 6% up to a mean of 10%. The omega-3 index
(Fig. 2) increased from a mean of 7.2% at baseline to
9.2% at 4 weeks, i.e. at the end of the treatment period
with the lowest dose of 50 mg/kg/day, to 13.1% at
8 weeks which was after end of treatment with the inter-
mediate dose of 150 mg/kg/day and finally to 18.3% at
the end of treatment with the high dose of 450 mg/kg/
day at 12 weeks. During the 12-weeks of treatment with
the vehicle control substance, which contained no EPA
and DHA, the mean omega-3 index in the control group
remained essentially unchanged as it only was reduced
from 6.0% at baseline to 5.8% (Fig. 2).
Following cessation of treatment, the membrane con-
centration of EPA and DHA in the treated group de-
clined consistent with first-order elimination kinetics
(Fig. 1). The omega-3 index was reduced from a mean of
18.3% at the end of treatment to a mean of 11.8%
2 weeks into the wash-out period, and 8 weeks after end
of treatment the mean omega-3 index in the treated
group was 8.8% (Fig. 2). As seen from the figure the two
fatty acids that constitute the omega-3 index, EPA and
DHA, have different kinetics and the rate and extent of
increase and decrease of the index are clearly affected
differently by the two FAs.
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The relative concentration of the omega-3 variant of
docosapentaenoic acid (DPA; C22:5n3), which may be
considered a metabolite of EPA, was higher than for
EPA at baseline; the mean was 2.8% and increased to a
mean of 4.5% at the end of the 12-week treatment
(Fig. 5).
The mean fractions of 22 other fatty acids in erythro-
cyte membranes at each sampling time-point in the
treated and control animals are presented in Table 1.
These data are further visualized in Figs. 3, 4 and 5. The
erythrocyte membrane fraction of the saturated FAs was
apparently unchanged when the omega-3 FAs increased.
The less abundant myristic acid (C14:0), arachidic acid
(C20:0), behenic acid (C22:0) and lignoceric acid (C24:0)
showed no consistent trend of increase or decrease
(Fig. 3). All these FAs were present at <1% at baseline.
The relative fraction of the major saturated FAs, palmitic
acid (C16:0) and stearic acid (C18:0), which both were
present in the membrane at a fraction of >15% at baseline,
was unchanged throughout the 20 weeks the study lasted
(Table 1 and Fig. 5). On the other hand, the relative frac-
tions of most of the unsaturated omega-6 FAs were clearly
altered during the study as the fraction of EPA and DHA
increased, but with some exceptions.
A considerable reduction was seen for arachidonic acid
(C20:4n6) which was reduced from a mean of 11.7 to
8.1% at 12 weeks, i.e. a reduction of approximately 30%
from baseline (Fig. 5). During the 8-week wash-out
Fig. 1 Individual concentrations of the main omega-3 fatty acids, EPA and DHA, in erythrocyte membranes, given as % of total fatty acids measured.
Dotted lines represent control animals, solid lines represent treated animals which were given 50 mg/kg/day of the omega-3 rich phospholipids during
week 1–4, 150 mg/kg/day during week 4–8 and 450 mg/kg/day during week 8–12. No treatment was given during week 12–20
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period a clear rebound effect was observed and at the
end of this period, the arachidonic acid level was only
6% lower than at baseline. Another abundant unsatur-
ated FA, linoleic acid (C18:2n6) with a baseline level of
22%, was reduced down to 17.1% after the 12 week treat-
ment (Fig. 5), a relative reduction of 27%. Oleic acid
(C18:1n9) had a mean baseline level of 10.4% in the
treated group and was reduced to a mean of 9.1% at the
end of treatment (Fig. 5), which represents a relative
reduction of about 12%. The fraction of both these FAs
approached their baseline levels during the 8 week
wash-out period. Alpha-linolenic acid (C18:3n3) and
gamma-linolenic acid (C18:3n6), both polyunsaturated
FAs present at very low levels in the membranes, were
both reduced during treatment with the long-chain
omega-3 rich phospholipids (Fig. 3). For all FAs being
reduced during treatment, the extent of reductions were
apparently depending on the dosages of EPA and DHA
and the reductions were always most prominent during
weeks 8–12 of treatment where the highest dose of
450 mg phospholipids/kg/day was administered.
The two medium-abundant unsaturated omega-6 FAs,
dihomo-g-linolenic acid (C20:3n6) and docosatetraenoic
acid (C22:4n6), had the largest relative reduction of all
FAs measured. The former FA was reduced by almost
60%; from a mean fraction of 1.84% at baseline to 0.75%
at 12 weeks, while the latter was reduced by 72%, i.e.
from a mean fraction of 1.39% at baseline to a mean of
0.39% at 12 weeks (Fig. 4).
Three trans-FAs were measured in the erythrocyte
membranes, palmitelaidic acid (C16:1n7t), elaidic acid
(C18:1n9t) and linoelaidic acid (C18:2n6t). None of these
were abundant in the membranes as all three had a rela-
tive fraction of around 0.2% at baseline, but they appeared
unchanged throughout the 20 weeks the study lasted
(Fig. 3).
Generally, for all FAs which changed their relative con-
centration in the erythrocyte membranes, a clear rebound
effect was observed and most of them were close to the
baseline levels 8 weeks after cessation of treatment with
the omega-3 rich phospholipid preparation.
The results from the analyses of endocannabinoids
and endocannabinoid-like compounds in plasma are
summarized in Table 2. As indicated by the standard
error of the means given in the table, the plasma con-
centrations of these compounds showed a marked vari-
ation between the animals and for some of the animals,
including the controls, the concentrations also varied
considerably from one time-point to the next. However,
when adjusting the mean of the three animals in the
treated group with the mean for the control group, the
pattern for each of the endocannabinoid-type com-
pounds in the treated group was generally consistent
with the changes in the erythrocyte concentrations of
the related FAs. Anandamide (arachidonoylethanola-
mide) and 2-AG are downstream derivatives of arachi-
donic acid and showed a decreasing trend in parallel
with the decreased fraction of their parent FA in eryth-
rocytes. EPA-ethanolamide, an endocannabinoid-like
mediator ultimately formed from EPA, increased in par-
allel to the increased fraction of EPA in erythrocytes.
DHA-ethanolamide, ultimately formed from DHA,
Fig. 2 Individual values for Omega-3 index, defined as the sum of EPA and DHA as % of total fatty acids in the erythrocyte membrane. Dotted
lines represent control animals, solid lines represent treated animals which were given 50 mg/kg/day of the omega-3 rich phospholipids during
week 1–4, 150 mg/kg/day during week 4–8 and 450 mg/kg/day during week 8–12. No treatment was given during week 12–20
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Table 1 Mean fractions of fatty acids in erythrocyte membranes of the non-human primates (n = 3 in each of the two groups) at
baseline, during and after treatment with the omega-3 rich phospholipid preparation, ranked according to increasing carbon chain-
length and double-bonds
Fatty acid Group Baseline Week after start of treatment
2 4 6 8 10 12 14 16 18 20
Myristic C14:0 Control 0.18% 0.16% 0.18% 0.19% 0.16% 0.13% 0.17% 0.17% 0.16% 0.14% 0.17%
Treated 0.23% 0.22% 0.22% 0.19% 0.21% 0.21% 0.20% 0.15% 0.21% 0.19% 0.20%
Palmitic C16:0 Control 20.7% 21.0% 21.6% 21.7% 21.3% 20.8% 20.5% 20.6% 21.4% 20.3% 20.8%
Treated 21.9% 22.5% 22.7% 22.0% 22.5% 23.4% 21.9% 22.5% 22.3% 21.8% 21.4%
Palmitoleic C16:1n7 Control 0.15% 0.14% 0.16% 0.15% 0.14% 0.14% 0.15% 0.14% 0.13% 0.13% 0.13%
Treated 0.27% 0.28% 0.28% 0.22% 0.20% 0.15% 0.15% 0.19% 0.23% 0.22% 0.22%
Palmitelaidic C16:1n7t Control 0.07% 0.07% 0.07% 0.07% 0.08% 0.06% 0.08% 0.07% 0.07% 0.06% 0.07%
Treated 0.12% 0.14% 0.14% 0.14% 0.15% 0.16% 0.17% 0.12% 0.13% 0.12% 0.12%
Stearic C18:0 Control 18.1% 18.1% 18.1% 18.3% 18.0% 17.6% 17.8% 18.1% 18.0% 17.8% 17.9%
Treated 15.9% 16.1% 16.0% 16.0% 16.4% 15.2% 15.7% 16.5% 16.2% 16.0% 16.0%
Oleic C18:1n9 Control 9.54% 9.49% 9.73% 9.72% 9.63% 9.50% 9.49% 9.59% 9.52% 9.30% 9.34%
Treated 10.4% 10.2% 9.98% 9.43% 9.45% 8.88% 9.14% 9.80% 9.73% 9.72% 9.46%
Elaidic C18:1n9t Control 0.14% 0.13% 0.14% 0.15% 0.14% 0.15% 0.16% 0.17% 0.12% 0.12% 0.12%
Treated 0.14% 0.15% 0.15% 0.15% 0.17% 0.18% 0.17% 0.16% 0.14% 0.13% 0.12%
Linoleic C18:2n6 Control 22.7% 22.1% 22.7% 22.5% 22.4% 23.3% 23.4% 23.6% 24.8% 25.4% 25.4%
Treated 22.4% 20.3% 20.8% 19.0% 18.9% 16.7% 17.1% 21.2% 23.4% 23.9% 24.1%
Linoelaidic C18:2n6t Control 0.30% 0.23% 0.25% 0.25% 0.19% 0.19% 0.18% 0.16% 0.17% 0.14% 0.17%
Treated 0.26% 0.21% 0.25% 0.16% 0.18% 0.15% 0.16% 0.15% 0.16% 0.14% 0.15%
alpha-linolenic C18:3n3 Control 0.20% 0.20% 0.26% 0.25% 0.27% 0.31% 0.31% 0.33% 0.38% 0.38% 0.38%
Treated 0.21% 0.22% 0.25% 0.22% 0.20% 0.18% 0.20% 0.28% 0.34% 0.35% 0.33%
gamma-linolenic C18:3n6 Control 0.10% 0.09% 0.09% 0.07% 0.10% 0.11% 0.10% 0.11% 0.10% 0.08% 0.09%
Treated 0.09% 0.09% 0.09% 0.07% 0.07% 0.04% 0.05% 0.06% 0.08% 0.07% 0.09%
Arachidic C20:0 Control 0.35% 0.35% 0.35% 0.35% 0.37% 0.35% 0.36% 0.37% 0.35% 0.37% 0.38%
Treated 0.32% 0.31% 0.33% 0.32% 0.34% 0.32% 0.32% 0.33% 0.34% 0.34% 0.37%
Eicosenoic C20:1n9 Control 0.52% 0.49% 0.51% 0.49% 0.50% 0.47% 0.45% 0.45% 0.44% 0.43% 0.45%
Treated 0.59% 0.55% 0.55% 0.51% 0.52% 0.44% 0.44% 0.46% 0.46% 0.45% 0.49%
Eicosadienoic C20:2n6 Control 0.79% 0.73% 0.70% 0.69% 0.68% 0.73% 0.73% 0.72% 0.75% 0.74% 0.74%
Treated 0.74% 0.72% 0.71% 0.64% 0.62% 0.55% 0.52% 0.69% 0.70% 0.72% 0.74%
Dihomo-g-linolenic C20:3n6 Control 1.27% 1.22% 1.23% 1.21% 1.13% 1.22% 1.23% 1.23% 1.20% 1.10% 1.12%
Treated 1.84% 1.61% 1.53% 1.15% 1.06% 0.81% 0.75% 1.12% 1.28% 1.36% 1.46%
Arachidonic C20:4n6 Control 13.9% 14.3% 13.4% 13.4% 13.7% 13.8% 13.9% 13.6% 12.8% 13.0% 12.6%
Treated 11.7% 11.9% 10.8% 10.5% 9.41% 8.49% 8.10% 8.63% 8.63% 9.53% 9.88%
Behenic C22:0 Control 0.40% 0.43% 0.36% 0.35% 0.45% 0.43% 0.41% 0.43% 0.36% 0.46% 0.40%
Treated 0.40% 0.38% 0.36% 0.42% 0.41% 0.37% 0.41% 0.38% 0.37% 0.39% 0.41%
Docosatetraenoic C22:4n6 Control 1.33% 1.33% 1.32% 1.31% 1.33% 1.34% 1.40% 1.36% 1.29% 1.30% 1.29%
Treated 1.39% 1.24% 1.11% 0.87% 0.70% 0.49% 0.39% 0.42% 0.47% 0.64% 0.74%
Docosapentaenoic C22:5n3 Control 2.10% 2.07% 2.09% 2.13% 2.13% 2.14% 2.12% 2.04% 1.95% 2.02% 2.06%
Treated 2.75% 3.18% 3.42% 3.93% 4.07% 4.36% 4.53% 4.16% 3.74% 3.65% 3.63%
Docosapentaenoic C22:5n6 Control 0.40% 0.54% 0.34% 0.36% 0.49% 0.48% 0.39% 0.41% 0.27% 0.42% 0.40%
Treated 0.41% 0.38% 0.30% 0.48% 0.43% 0.38% 0.39% 0.31% 0.29% 0.41% 0.46%
Lignoceric C24:0 Control 0.40% 0.46% 0.33% 0.30% 0.48% 0.47% 0.41% 0.39% 0.31% 0.46% 0.39%
Treated 0.39% 0.35% 0.32% 0.48% 0.44% 0.39% 0.44% 0.35% 0.32% 0.41% 0.44%
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showed, however, no consistent trend of increase or
decrease despite the observed increase in the fraction of
DHA in the erythrocyte membranes. Two other
endocannabinoid-like compounds, palmitoylethanola-
mide and oleoylethanolamide, ultimately formed from
the saturated FAs palmitic acid and oleic acid, respect-
ively, did not show any trend of change in the plasma
concentration which is in line with the unchanged
erythrocyte fraction of their parent FAs. Similar to the
FAs in the erythrocyte membranes, the plasma concen-
tration of the affected FA metabolites returned towards
the baseline or even beyond the baseline levels after ces-
sation of treatment with the phospholipid preparation.
Discussion
The main finding of the present investigation is that
when the fractions of the long-chain omega-3 FAs EPA
and DHA in erythrocyte membranes increased as a re-
sult of oral treatment with an omega-3 rich phospholipid
preparation extracted from krill oil, the FAs reduced
were only other unsaturated FAs and in particular
omega-6 FAs. None of the saturated FAs changed their
relative presence in the membranes, whether they were
abundant or not. The relative fraction of monounsatu-
rated FAs seems to be less affected than polyunsaturated
ones. Also the measured trans FAs, although present
only in very low fractions, appeared unchanged during
the treatment period. It is of note that the relative frac-
tions of EPA and DHA increased markedly as a result of
treatment, and the omega-3 index, representing the sum
of EPA and DHA in the membranes, increased from
7.3% at baseline to 18.2% at the end of the 12-week
treatment. The omega-3 dose-levels applied in this study
are relevant in a human setting since the dose-levels of
EPA +DHA used, when converted to human equivalent
dose (HED) levels, amount to 300, 860 and 2580 mg/day
to an adult human of 60 kg. The HED is calculated
based on body surface area and obtained by dividing the
dose in the monkeys, given as mg/kg, by 3.1 and multi-
plying by the human body weight [12].
Our data are in line with the results from the study by
Katan et al. [13], who gave three doses of fish oil to
adults and measured omega-3 fatty acids as well as two
omega-6 fatty acids, linoleic and arachidonic acids, in
erythrocytes. The omega-3 fatty acids increased dose-
dependently while the two omega-6 fatty acids were
reduced dose-dependently. These authors did not re-
port concentrations of any saturated fatty acids. How-
ever Ramprasath and co-workers compared the
increase in omega-3 index, omega-6:omega-3 ratio,
total saturated fatty acids, total monounsaturated fatty
acids and total omega-6 fatty acids after krill oil and
fish oil after 4 weeks of treatment and found that
total saturated fatty acids were unchanged despite a
clear increase in omega-3 index and a reduction in
the omega-6:omega-3 ratio. These authors did not
specify the levels of individual fatty acids except for
EPA, DHA and DPA [14].
The potential consequences of these changes in the
composition of the cell membranes induced by the ad-
ministration of EPA and DHA were not investigated in
this study but the assumption is that the balance be-
tween saturated and unsaturated FAs has implications
for membrane fluidity and thereby cellular function [15].
Therefore, the observation that the membrane content
of saturated vs. unsaturated FAs is relatively unaffected
by the introduction of EPA and DHA is interesting. Of
note are also the changes in the plasma concentrations
of endocannabinoids and endocannabinoid-like media-
tors, which generally followed the changes in erythrocyte
FA abundance. This was not surprising since these me-
diators are ultimately derived from membrane phospho-
lipids containing the corresponding fatty acids in either
the sn-1 (in the case of acylethanolamides) or sn-2 (in
the case of 2-acylglycerols such as 2-AG) positions. Due
to the various physiological effects of the endocannabi-
noids, in particular their regulatory effects on appetite,
food intake, adipose tissue and ectopic fat accumulation
and insulin sensitivity [16], a reduction of the relative
abundance of their precursors and, subsequently, of their
biosynthesized amounts, may have significant biological
implications. Thus, the trend for the reduction in arachi-
donoylethanolamide (anandamide) and 2-AG levels may
explain in part some of the beneficial metabolic effects
observed with the krill oil preparation [11]. However,
also EPA and DHA-derived ethanolamides are emerging
as bona fide non-endocannabinoid mediators with po-
tential anti-inflammatory actions [17] and we found here
Table 1 Mean fractions of fatty acids in erythrocyte membranes of the non-human primates (n = 3 in each of the two groups) at
baseline, during and after treatment with the omega-3 rich phospholipid preparation, ranked according to increasing carbon chain-
length and double-bonds (Continued)
Nervonic C24:1n9 Control 0.41% 0.50% 0.30% 0.26% 0.48% 0.45% 0.39% 0.38% 0.25% 0.45% 0.33%
Treated 0.46% 0.44% 0.33% 0.58% 0.48% 0.40% 0.46% 0.33% 0.30% 0.42% 0.45%
Dose (mg phospholipids/kg bw/day) 50 150 450 0
Dose (mg [EPA/DHA]/kg bw/day) 9.35/5.48 28.0/16.4 84.1/49.3 0/0
Doses of administered phospholipids and of EPA and DHA are shown at the end of the table
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Fig. 3 (See legend on next page.)
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that EPA-ethanolamide, which is ultimately derived
from the long chain omega-3 FA whose levels increased
the most and most consistently in our study, i.e. EPA,
was also increased following treatment with krill oil
phospholipids.
The finding that the main effect of a high intake of
omega-3 FAs is a progressive change in the relative abun-
dance of the polyunsaturated FAs and not a displacement
of saturated FAs from the cell membrane is also support-
ing the theory that the reported anti-inflammatory ef-
fects of omega-3 FAs may, at least partly, be due to a
reduced membrane concentration of arachidonic acid
which in turn should lead to reduced production of
proinflammatory arachidonic acid metabolites like
prostaglandins, leukotriens and thromboxanes [18].
Our data show that the fraction of arachidonic acid in
the membranes was reduced by about 30% as a result
of the 12-week treatment with increasing doses of the
omega-3 rich phospholipids. An additional aspect is the
effects of the so-called ‘specialized proresolving media-
tors’; the resolvins, protectins and maresins, all mole-
cules biosynthesized from long-chain omega-3 FAs and
shown to stimulate proresolving cellular processes such
as inhibition of neutrophil infiltration, enhancement of
macrophage phagocytosis of bacteria and efferocytosis
of cellular debris, and reduction of inflammatory pain
through specific G-protein coupled receptors [19]. The
proresolving effects of these specialized proresolving
mediators would be expected to work in concert with
the decreased proinflammatory effects caused by a re-
duced production of arachidonic acid metabolites and
together, these two mechanisms might to a large extent
explain the beneficial effects the long-chain omega-3
FAs have on inflammation.
The long-chain omega-3 FAs used in the present study
were administered to the animals as phospholipids. The
most common form of omega-3 FAs in the human diet
is, however, triglycerides since omega-3 FAs in fish are
mostly in this chemical form [2]. Our study did not
compare the outcome of administration of omega-3 FAs
as phospholipids and as triglycerides and the results
obtained in our study should therefore not be general-
ized as effects of any omega-3 preparation used. Since
omega-3 FAs in cell membranes mostly are incorporated
in phospholipids, it might be that the chemical form ad-
ministered has implications on how the FAs are distrib-
uted in cell membranes. There has been some debate in
the literature whether delivery of long-chain omega-3
FAs as phospholipids, which is the case when the source
is krill oil, is more efficient for building up the omega-3
index than when delivering these FAs as triglycerides
like in most fish oils. A recent article by Yurko-Mauro
and co-workers concluded that giving EPA and DHA in
either ethyl ester, triglyceride or phospholipid form for
4 weeks created similar plasma and erythrocyte levels of
the FAs [20]. However, other literature has indicated a
more efficient uptake of these omega-3 FAs when given
as krill oil than with fish oil [21, 22], resulting in higher
omega-3 indices after dose-corrections. From a general
point of view one would expect FAs to be absorbed al-
most completely from forms that are natural, i.e. triglyc-
erides and phospholipids, since the digestion of fat in
the gastrointestinal tract is tailor-made for optimal
absorbtion of this type of nutrients [23]. It is of note,
however, that Ramprasath and coworkers have published
their observation that the content of phospholipids in
krill oil may have an impact on the bioavailability of the
omega-3 FAs [24]. Given that the preparation tested in
(See figure on previous page.)
Fig. 3 Mean concentrations and SEM of the less abundant (<1% at study start) fatty acids in erythrocyte membranes, given as % of total fatty
acids measured, shown in the order of increasing chain length. Blue dotted line represents the control group, red solid line represents the treated
group which was given 50 mg/kg/day of the omega-3 rich phospholipids during week 1–4, 150 mg/kg/day during week 4–8 and 450 mg/kg/day
during week 8–12. No treatment was given during week 12–20
Fig. 4 Mean concentrations and SEM of the median abundant (>1% but <2% at study start) fatty acids in erythrocyte membranes, given as % of
total fatty acids measured, shown in the order of increasing chain length. Blue dotted line represents the control group, red solid line represents
the treated group which was given 50 mg/kg/day of the omega-3 rich phospholipids during week 1–4, 150 mg/kg/day during week 4–8 and
450 mg/kg/day during week 8–12. No treatment was given during week 12–20
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our study was highly purified with a phospholipid con-
tent of >98%, this may have led to a higher increase in
the omega-3 index than would a normal krill-oil prepar-
ation with an approximately 40% phospholipid content,
provided comparable doses of omega-3 FAs.
The omega-3 index determined in erythrocyte mem-
branes is well correlated with omega-3 levels in other
tissues, in particular heart tissue [25]. A high omega-3
index, preferably above 8%, has been shown to be
strongly correlated with a reduced risk of sudden cardiac
death [26]. Furthermore, a low omega-3 index has also
been shown to correlate with an increased risk for dis-
ease of the central nervous system like depression [27]
and an increased intake of long-chain omega-3 FAs has
been suggested as a treatment strategy for maintaining
cognitive health into older age [28].
An obvious limitation of our study is the relatively low
number of animals included in each of the control and
treated groups, which precludes a statistical analysis of
the data. However, given that the species used is a non-
human primate, animal ethics suggests that the number
used should be as low as possible, provided meaningful
data can be obtained. Animals fed a standard diet over
long periods of time, like those in the present study, will
generally have much less variation in their baseline FA
profiles than humans who have a variable diet and there-
fore more heterogeneous FA profiles. This was con-
firmed by the low variation in erythrocyte FA abundance
between the animals in the control group. Also the con-
sistent changes in the FAs in the treated animals indicate
that the trends observed are reliable.
Conclusions
Feeding non-human primates with increasing doses of
an omega-3 rich phospholipid preparation extracted
from krill oil caused a dose-related increase in the frac-
tion of the long-chain omega-3 FAs EPA and DHA in
erythrocyte membranes and a dose-related decrease of
other polyunsaturated FAs, and in particular omega-6
polyunsaturated FAs. Erythrocyte concentrations of satu-
rated fatty acids remained unchanged throughout the ex-
perimental period. Hence, increasing the omega-3 index
Fig. 5 Mean concentrations and SEM of the most abundant (>2% at study start) fatty acids in erythrocyte membranes, given as % of total fatty
acids measured, shown in the order of increasing chain length. Blue dotted line represents the control group, red solid line represents the treated
group which was given 50 mg/kg/day of the omega-3 rich phospholipids during week 1–4, 150 mg/kg/day during week 4–8 and 450 mg/kg/day
during week 8–12. No treatment was given during week 12–20
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does apparently not alter the ratio of unsaturated vs.
saturated FAs but only the relative concentrations of
unsaturated FAs. The plasma concentrations of six
endocannabinoid-type mediators changed accordingly,
as those being downstream arachidonic acid decreased,
those downstream the saturated palmitic and oleic acids
remained unchanged, and a downstream EPA metabolite
increased.
Methods
Test and control items
The product tested in the current investigation is a prep-
aration of purified (>98% pure) phospholipids extracted
from krill-oil, rich in the long-chain omega-3 fatty acids
eicosapentaenoic acid (EPA; C20:5n3) and docosahexae-
noic acid (DHA; C22:6n3). The final product was formu-
lated to improve its floating properties, thus making it
easier to administer, and had the following composition:
phospholipids 84% (840 mg/ml), polyethylene glycol
with MW 400 (PEG400) 12.5% and ethanol 3.5%. The
abundance of FAs in the end-product was analyzed by
methylation of the FAs followed by gas-chromatography
and 25 fatty acids were detected and quantified. The
EPA and DHA contents were 15.7% (157 mg/g) and
9.2% (92 mg/g), respectively. In addition, five other FAs
were present in the end-product with an abundance of
more than 1% (10 mg/g): myristic acid (C14:0) 1.1%,
palmitic acid (C16:0) 13.2%, oleic acid (C18:1n9) 2.1%, cis-
vaccenic acid (C18:1n11) 3.1% and stearidonic acid
(C18:4n3) 1.3%. All other detected FAs in the end-product
were below 1%. The formulation used has been proven
stable for at least 6 months.
The control substance was designed to be a vehicle
control and was made similarly as the test substance but
Table 2 Concentrations (pmol/ml) of the endocannabinoid-type compounds measured in plasma from the non-human primates




Group Value Baseline Week after start of treatment
2 4 6 8 10 12 14 16 18 20
Anandamide Control Mean 4.24 4.80 5.60 4.31 4.82 4.66 6.02 6.19 2.82 5.19 5.15
SEM 2.00 1.18 2.17 0.93 0.80 0.91 3.84 2.65 0.77 1.38 1.67
Treated Mean 3.07 3.40 2.86 2.98 2.86 3.34 2.28 3.64 4.25 4.05 4.44
SEM 0.52 1.54 0.93 0.56 0.92 1.35 0.97 1.35 1.69 1.53 0.43
2-arachidonoylglycerol Control Mean 14.3 21.0 23.1 21.9 27.8 20.7 28.6 22.7 19.0 18.6 22.4
SEM 5.5 13.8 15.9 11.1 19.2 15.2 20.6 12.3 11.8 11.3 15.5
Treated Mean 16.8 19.2 13.3 9.14 11.7 4.42 8.48 15.0 26.5 16.5 26.4
SEM 6.4 9.2 7.9 1.12 3.3 1.60 4.20 10.0 19.1 9.1 11.3
EPA ethanolamide Control Mean 1.36 1.45 0.91 1.25 0.22 0.57 1.00 1.07 2.07 2.04 2.84
SEM 0.49 0.29 0.16 0.31 0.07 0.20 0.07 0.71 0.84 0.62 1.06
Treated Mean 0.47 1.04 1.05 1.13 0.85 1.00 1.07 0.58 1.34 1.55 0.63
SEM 0.13 0.48 0.34 0.26 0.24 0.17 0.26 0.22 0.93 0.51 0.35
DHA ethanolamide Control Mean 1.23 4.67 5.17 6.64 4.95 4.63 4.61 2.28 3.89 5.82 4.80
SEM 0.29 1.35 2.09 1.95 2.45 2.03 2.06 1.10 1.45 2.49 1.91
Treated Mean 3.06 6.63 8.03 7.24 6.60 7.41 4.96 3.49 5.57 5.97 6.76
SEM 1.68 3.17 2.34 1.52 1.59 1.12 0.89 0.39 1.30 2.83 2.93
Palmitoyl ethanolamide Control Mean 54.7 64.7 58.3 94.7 53.5 71.9 89.9 30.8 24.7 59.3 120
SEM 4.70 10.3 15.3 30.5 12.7 11.2 7.80 4.70 1.50 20.8 36.3
Treated Mean 66.2 62.5 65.6 86.1 58.6 48.4 69.1 78.8 39.5 92.0 120
SEM 19.2 11.9 14.7 17.3 13.9 9.20 2.40 23.7 8.3 31.5 47.9
Oleoyl ethanolamide Control Mean 24.2 24.3 19.0 20.3 30.5 28.5 14.0 29.1 17.6 29.3 31.0
SEM 4.44 1.50 2.25 2.23 1.55 2.65 1.35 5.26 4.10 4.60 2.28
Treated Mean 24.2 22.3 16.0 20.3 24.8 29.9 14.4 36.9 18.0 39.7 45.5
SEM 3.63 6.86 2.05 2.49 6.63 7.76 2.54 15.01 3.03 14.54 9.89
Dose (mg phospholipids/kg bw/day) 50 150 450 0
Dose (mg [EPA/DHA]/kg bw/day) 9.35/5.48 28.0/16.4 84.1/49.3 0/0
Doses of phospholipids and of EPA and DHA are shown at the end of the table
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by substituting the phospholipids with water. Therefore,
the control substance contained 84% water, 12.5%
PEG400 and 3.5% ethanol.
Animals
Six type-2 diabetic and dyslipidemic cynomolgus mon-
keys (Macaca fascicularis) were selected for the study,
after screening a total of 34 animals. Inclusion criteria
were predefined and were related to diabetes parameters
(HbA1c, glucose and insulin) and blood lipid levels
(triglycerides, total cholesterol, low-density lipoprotein
cholesterol (LDL-c) and high-density lipoprotein choles-
terol (HDL-c)). The results from the screening as well as
details of housing conditions and care are described in
[11]. Vital data of the monkeys included in the study are
given in Table 3.
The animals were fed a standard monkey diet contain-
ing crude protein (≥16%), crude fat (≥4%), moisture
(≤10%), ash (≤7%), fiber (≤4%), calcium (0.8–1.2%) and
phosphorus (0.6–0.8%). The content of omega-3 fatty
acids in the diet had not been determined by the sup-
plier (Beijing Keao Xieli Feed Co. Ltd., Beijing, P. R.
China). Care and use of the animals were conducted in
accordance with all applicable assessment and accredit-
ation of the laboratory animal care (AAALAC) regula-
tions and guidelines. Crown bioscience institutional
animal care and use committee (IACUC) approved all
animal procedures used in the study. All the procedures
related to handling, care and treatment of the animals in
this study were performed according to the guidelines
approved by AAALAC. After completion of the study
the animals were returned to the stock of diabetic mon-
keys held at Crown Biosciences for a recovery period
and following this they were allowed to be used in other
studies.
Dosing
The test and control items were dosed once per day. Just
prior to administration the product was warmed up to
35 °C and mixed with lukewarm water in a syringe in
the ratio 1:5 to become an emulsion. Immediately there-
after, the emulsion was administered by connecting a
naso-/oral gastric tube to the syringe and inserting it
into the stomach. To ascertain that the entire dose was
given the tube was flushed with lukewarm water. The
control item was handled in the same way as the test
item.
The control and test items were given by gavage, 1 h
after the first feeding of the day. The control article was
administered at the same volume/kg as the test article.
For the first 4 weeks, a phospholipid dose of 50 mg/kg/
day was given, the next 4 weeks the dose was 150 mg/
kg/day and for the last 4 weeks 450 mg/kg/day. These
phospholipid doses resulted in EPA/DHA doses of 9.35/
5.48 mg/kg/day, 28.0/16.4 mg/kg/day and 84.1/49.3 mg/
kg/day, respectively. Dosing volumes were based on
body weights recorded bi-weekly. When converted to
human equivalent dose (HED) these doses were equiva-
lent to approximately 1, 3 and 10 g phospholipids/day,
respectively, to an adult person of 70 kg.
Blood sampling
Blood was sampled bi-weekly and centrifuged at 3000–
3500 rpm for 10–15 min at room temperature. After
discarding the plasma and buffy coat a minimum of
0.25 ml red blood cells (RBC) from the middle of the RBC
layer was collected and transferred to a well-labeled storage
cryovial. The samples were frozen at −80 °C until being
shipped out on dry ice for analysis.
Analysis
The analysis of fatty acids in the erythrocyte membranes
was performed by OmegaQuant, Sioux Falls, SD USA, by
gas chromatography (GC) with flame ionization detection
[6]. OmegaQuant is a Clinical Laboratory Improvement
Amendments (CLIA)-certified laboratory and the assay
for fatty acid analysis has been validated and standardized
[29]. The company has not published all details of the
method and the validation of it since they consider this
information proprietary. However, the coefficient of vari-
ation (CV) of the method for EPA, DHA and arachidonic
acid is reported to be between 5 and 8% for all three fatty
acids [29] and for the omega-3 index the CV is reported
to be <5% [6].
Unwashed, packed erythrocytes were transferred to a
screw-cap glass vial. Methanol containing 14% boron
trifluoride (Sigma-Aldrich, St. Louis, MO) and hexane
(EMD Chemicals, USA) were added sequentially. The
vial was briefly vortexed and heated in a hot bath at
100 °C for 10 min. After cooling, HPLC grade water was
added, the tubes were recapped, vortexed and centri-
fuged to separate layers. An aliquot of the hexane layer
was transferred to a GC vial. GC was carried out using a
Table 3 Vital data of the six non-human primates included in
the study
Group Animal ID Sex Age (years) Bodyweight (kg)
Control
Control no. 1 M 14 9.22
Control no. 2 M 15 10.0
Control no. 3 F 13 4.32
Treated
Treated no. 1 M 14 8.30
Treated no. 2 F 21 7.34
Treated no. 3 M 20 10.8
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GC2010 Gas Chromatograph (Shimadzu Corporation,
Columbia, MD) equipped with an SP2560, 100-m fused
silica capillary column (0.25 mm internal diameter, 0.2
um film thickness; Supelco, Bellefonte, PA).
FAs were identified by comparison with a standard
mixture of fatty acids characteristic of RBC (GLC OQ-
A, NuCheck Prep, Elysian, MN) which was also used to
determine individual fatty acid calibration curves. In
addition to EPA (C20:5n3) and DHA (C22:6n3), the fol-
lowing 22 fatty acids were quantified: myristic (14:0),
palmitic (16:0), palmitoleic (C16:1n7), palmitelaidic
(C16:1n7t), stearic (18:0), oleic (C18:1n9), elaidic
(C18:1n9t), linoleic (C18:2n6), linoelaidic (C18:2n6t),
alpha-linolenic (C18:3n3), gamma-linolenic (C18:3n6),
arachidic (20:0), eicosenoic (C20:1n9), eicosadienoic
(C20:2n6), dihomo-g-linolenic (C20:3n6), arachidonic
(C20:4n6), behenic (22:0), docosatetraenoic (C22:4n6),
docosapentaenoic (C22:5n3 and C22:5n6), lignoceric
(24:0) and nervonic (C24:1n9) acids. The chromato-
graphic conditions used in this study were sufficient to
isolate the C16:1trans isomers and the C18:2, 9 t-12c,
9 t-12 t, and 9c-12 t isomers, which are reported as
C18:2n6t. However, each individual C18:1 trans mo-
lecular species (i.e., C18:16 thru 13) could not be segre-
gated but appeared as two blended peaks that eluted
just before oleic acid. The areas of these two peaks were
summed and referred to a C18:1 trans.
FA composition was expressed as a percent of total
identified fatty acids. The omega-3 index was calculated
as the sum of percent fraction of EPA (C20:5n3) and
DHA (C22:6n3).
The concentrations of the endocannabinoids ananda-
mide (AEA), 2-arachidonoylglyceride (2-AG), EPA
ethanolamide (EPAEA), DHA ethanolamide (DHAEA),
palmitoyl ethanolamide (PEA) and oleoyl ethanolamide
(OEA) in plasma were analyzed as described previously
[30]. In brief, samples were dounce-homogenized and
extracted with chloroform/methanol/Tris-HCl 50 mM
pH 7.5 (2:1:1, v/v) containing internal deuterated stan-
dards for AEA, 2-AG, PEA and OEA quantification by
isotope dilution (10 pmol of [2H]8AEA and 50 pmol of
[2H]52AG, [
2H]4 PEA, [
2H]4 OEA (Cayman Chemicals,
MI, USA). Quantification of EPAEA and DHAEA was
done by using deuterated AEA as internal standard.
The lipid-containing organic phase was dried down,
weighed and pre-purified by open bed chromatography
on silica gel. Fractions were obtained by eluting the
column with 99:1, 90:10 and 50:50 (v/v) chloroform/
methanol. The 90:10 fraction was used for AEA, 2-AG,
PEA and OEA quantification by liquid chromatography-
atmospheric pressure chemical ionization-mass spec-
trometry (LC-APCI-MS), as previously described and
using selected ion monitoring at M + H+ values for the
four compounds and their deuterated homologues, as
described in [31, 32]. Pilot experiments showed that the
ratios between the peak areas of the M +H+ ions for
each of the non-deuterated compounds and those of a
known amount (10 or 50 pmol) of the corresponding
deuterated compounds (or of deuterated AEA in the
case of EPAEA and DHAEA) varied linearly with the
concentration of the non-deuterated compounds, over
the 0.1–1000 pmol range, and therefore were suitable
for quantification. The CV of these methods have also
been described in previous papers (see [32] and [33] for
recent reviews).
Data presentation and statistics
For the omega-3 FAs EPA and DHA, and for the omega-3
index, individual values for each of the 6 animals are pre-
sented graphically. For the other 22 FAs, mean values for
the control and treated groups are tabulated and mean
and SEM values presented graphically. For the endocanna-
binoids, mean and SEM values for the control and treated
groups are tabulated. Mean rather than median values
were used to describe the central tendency for each group,
despite the small group size, since this also made it pos-
sible to give SEM as a measure of spread. Due to the low
number of animals in each of the control and treated
groups, no comparison between groups based on statis-
tical criteria was performed.
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